Skip to content
Tenfell
Awarded contract
Published 20 Jul 2022

Bleeding Disorders including Haemophilia B

NHS England · London

Key facts

Awarded
14 Jun 2022
Contract starts
30 Jun 2022
Contract ends
30 Jun 2024
Procedure
Open procedure (above threshold)
Buyer type
Central government

Awarded to 8 suppliers

SupplierValue
Takeda UK Limited—
Pfizer Ltd—
Novo Nordisk—
Sobi (Swedish Orphan Biovitrum Ltd)—
Octapharma Limited—
Bio Products Laboratory—
CSL Behring UK Ltd—
LFB—

Description

NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B. Period of framework agreement: 1 July 2022 to 30 June 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.